$KPRX
KIORA PHARMACEUTICALS INC

2017 Q3 Form 10-Q Financial Statement

#000114420417058607 Filed on November 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q4 2016 Q3
Revenue $74.70K $160.0K $274.3K
YoY Change -72.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $1.280M $1.200M
YoY Change -13.33% -0.78% 26.32%
% of Gross Profit
Research & Development $3.176M $2.580M $2.449M
YoY Change 29.66% 86.96% 500.99%
% of Gross Profit
Depreciation & Amortization $4.536K $10.00K $404.00
YoY Change 1022.77%
% of Gross Profit
Operating Expenses $4.215M $3.860M $3.651M
YoY Change 15.43% 44.03% 169.71%
Operating Profit -$4.140M -$3.377M
YoY Change 22.6%
Interest Expense $304.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$264.00 $0.00 $298.00
YoY Change -188.59% -116.69%
Pretax Income -$4.140M -$3.700M -$3.380M
YoY Change 22.49% 37.55% 148.53%
Income Tax
% Of Pretax Income
Net Earnings -$4.140M -$3.700M -$3.377M
YoY Change 22.62% 37.55% 149.1%
Net Earnings / Revenue -5542.96% -2312.5% -1231.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$138.00 -$185.00 -$169.00
COMMON SHARES
Basic Shares Outstanding 9.586M shares 8.952M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.240M $3.640M $5.680M
YoY Change 62.68% -56.62% -42.74%
Cash & Equivalents $9.245M $3.680M $5.682M
Short-Term Investments
Other Short-Term Assets $360.0K $460.0K $530.0K
YoY Change -32.08% 283.33% 562.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables $37.35K $37.35K
Total Short-Term Assets $10.23M $4.154M $6.263M
YoY Change 63.35% -56.04% -37.55%
LONG-TERM ASSETS
Property, Plant & Equipment $20.00K $38.04K $42.58K
YoY Change -53.03% 18331.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $323.2K $55.31K $53.95K
YoY Change 499.07% 43.35% 44.83%
Total Long-Term Assets $5.830M $5.577M $4.354M
YoY Change 33.9% 9418.43% 6995.45%
TOTAL ASSETS
Total Short-Term Assets $10.23M $4.154M $6.263M
Total Long-Term Assets $5.830M $5.577M $4.354M
Total Assets $16.06M $9.731M $10.62M
YoY Change 51.27% 2.34% 5.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $660.0K $1.412M $1.403M
YoY Change -52.97% 238.07% 777.12%
Accrued Expenses $1.720M $1.671M $1.340M
YoY Change 28.41% 52.49% 435.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.64M $7.308M $6.161M
YoY Change 105.15% 113.63% 336.97%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities $1.210M $1.210M
YoY Change
Total Long-Term Liabilities $2.742M $2.752M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.64M $7.308M $6.161M
Total Long-Term Liabilities $2.742M $2.752M $0.00
Total Liabilities $15.38M $10.06M $7.371M
YoY Change 108.65% 194.07% 422.78%
SHAREHOLDERS EQUITY
Retained Earnings -$78.60M -$74.90M
YoY Change 20.45%
Common Stock $101.3K $95.86K
YoY Change 32.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $680.0K -$329.4K $3.245M
YoY Change
Total Liabilities & Shareholders Equity $16.06M $9.731M $10.62M
YoY Change 51.27% 2.34% 5.22%

Cashflow Statement

Concept 2017 Q3 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$4.140M -$3.700M -$3.377M
YoY Change 22.62% 37.55% 149.1%
Depreciation, Depletion And Amortization $4.536K $10.00K $404.00
YoY Change 1022.77%
Cash From Operating Activities -$2.520M -$2.050M -$2.330M
YoY Change 8.15% 32.26% 1270.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.520M -2.050M -2.330M
Cash From Investing Activities 0.000 0.000 -10.00K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -2.520M -2.050M -2.340M
YoY Change 7.69% 33.12% -127.05%
FREE CASH FLOW
Cash From Operating Activities -$2.520M -$2.050M -$2.330M
Capital Expenditures $0.00 $0.00 $10.00K
Free Cash Flow -$2.520M -$2.050M -$2.340M
YoY Change 7.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
40 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55314 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
323206 USD
CY2016Q4 eyeg Goodwill And Inprocess Research And Development
GoodwillAndInprocessResearchAndDevelopment
5438210 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
6 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Liabilities
Liabilities
15379968 USD
CY2016Q4 us-gaap Liabilities
Liabilities
10060023 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1210000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1210000 USD
CY2017Q3 eyeg Goodwill And Inprocess Research And Development
GoodwillAndInprocessResearchAndDevelopment
5438210 USD
CY2017Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1525896 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1525896 USD
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
6585 USD
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
16069 USD
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2742481 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2751965 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1038822 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1201804 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
4214800 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
3651249 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
298 USD
CY2017Q3 us-gaap Interest Expense
InterestExpense
304 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-264 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
298 USD
us-gaap Sales Revenue Net
SalesRevenueNet
407518 USD
us-gaap Sales Revenue Net
SalesRevenueNet
508889 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7253171 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5844951 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3540857 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4309737 USD
us-gaap Operating Expenses
OperatingExpenses
10794028 USD
us-gaap Operating Expenses
OperatingExpenses
10154688 USD
us-gaap Interest Expense
InterestExpense
912 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-375 USD
us-gaap Profit Loss
ProfitLoss
-10386885 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13267501 shares
us-gaap Investment Income Interest
InvestmentIncomeInterest
537 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3423 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6193 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10380692 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9642720 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4140104 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3376960 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10386510 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9645799 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17204778 shares
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9269535 shares
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3272 USD
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
715 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4137096 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3375947 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
74696 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
274289 USD
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-4140368 USD
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-3376662 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8499709 shares
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-344 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
649 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8611683 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-329421 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
700833 USD
eyeg Preferred Stock Issued During Period Value
PreferredStockIssuedDuringPeriodValue
1977500 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40718 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
6193 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10386885 USD
CY2017Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
679445 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13608 USD
us-gaap Share Based Compensation
ShareBasedCompensation
700833 USD
us-gaap Share Based Compensation
ShareBasedCompensation
390469 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
194364 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
35748 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3173 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-9786 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1083 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
15364 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-753513 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
704912 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6029600 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
48324 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
53342 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-200829 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5015231 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6361542 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
25000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
149746 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40718 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
56206 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10620417 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3501090 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
4160 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1053 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8394133 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5682374 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5609346 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2711759 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
185746 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1210000 USD
eyeg Stock Issued For Acquisition
StockIssuedForAcquisition
0 USD
eyeg Stock Issued For Acquisition
StockIssuedForAcquisition
2909766 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11922252 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3768698 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
9484 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1333069 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
323814 USD
eyeg Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
9300 USD
eyeg Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
6890 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
564650 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2378635 USD
CY2016Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1234000 shares
CY2016Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3400000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000 USD
us-gaap Depreciation
Depreciation
13608 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
564525 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
668802 USD
CY2017Q3 eyeg Clinical Trials Currrent
ClinicalTrialsCurrrent
977882 USD
CY2016Q4 eyeg Clinical Trials Currrent
ClinicalTrialsCurrrent
770158 USD
CY2017Q3 eyeg Consulting Expenses Current
ConsultingExpensesCurrent
5517 USD
CY2016Q4 eyeg Consulting Expenses Current
ConsultingExpensesCurrent
44983 USD
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
163703 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
174342 USD
CY2017Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1330000 shares
CY2017Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8800000 USD
CY2017Q2 eyeg Warrant Expiration Date
WarrantExpirationDate
2022-06-14
CY2016Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
100000000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6666667 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4931047 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11777703 shares
CY2017Q3 eyeg Money Market Funds Fair Value
MoneyMarketFundsFairValue
750946 USD
CY2017Q3 eyeg Contingent Consideration Funds Fair Value
ContingentConsiderationFundsFairValue
1210000 USD
CY2016Q4 eyeg Money Market Funds Fair Value
MoneyMarketFundsFairValue
1500882 USD
CY2016Q4 eyeg Contingent Consideration Funds Fair Value
ContingentConsiderationFundsFairValue
1210000 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18145 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4536 USD
CY2016Q3 us-gaap Depreciation
Depreciation
404 USD
CY2017Q3 us-gaap Depreciation
Depreciation
4536 USD
us-gaap Depreciation
Depreciation
649 USD
CY2017Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
12645 USD
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
12645 USD
CY2016Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1319289 shares
CY2017Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3285798 USD
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8800000 USD
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17204778 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10130883 shares
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9995828 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9997223 shares
CY2017Q2 eyeg Class Of Warrant Or Right Number Of Warrant Issued
ClassOfWarrantOrRightNumberOfWarrantIssued
6666667 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
550000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
720000 USD
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1113000 USD
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1209000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M13D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M6D
CY2017Q3 eyeg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
242000 USD
CY2016Q2 eyeg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
597000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
78000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
207000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y3M11D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.94
CY2016Q3 us-gaap Area Of Land
AreaOfLand
2300 sqft
CY1999Q1 eyeg License Expiration Period
LicenseExpirationPeriod
P12Y
CY1999Q1 us-gaap License Costs
LicenseCosts
12500 USD
CY2013Q3 us-gaap License Costs
LicenseCosts
50000 USD
CY2016Q2 us-gaap License Costs
LicenseCosts
15000 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17204778 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10130883 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1086736 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">1. Organization, Business</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">EyeGate Pharmaceuticals, Inc. (&#8220;EyeGate&#8221; or the &#8220;Company&#8221;) a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate&#8217;s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, EGP-437, that is delivered into the ocular tissues though its proprietary iontophoresis drug delivery system, the EyeGate&#174; II Delivery System. The Company is developing the EyeGate&#174; II Delivery System and EGP-437 combination product (together, the &#8220;EGP-437 Product&#8221;) for the treatment of various inflammatory conditions of the eye, including anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, post-cataract surgery for inflammation and pain, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the retina. Effective March 7, 2016, the Company acquired all of the capital stock of Jade Therapeutics, Inc. (&#8220;Jade&#8221;), a privately-held company developing locally-administered, polymer-based products designed to treat poorly-served ophthalmic indications (the &#8220;Jade Acquisition&#8221;). EyeGate and Jade are an integrated line of business developing ophthalmic solutions for a variety of ocular diseases and disorders.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 30, 2016, the Company completed a registered direct offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 441,000</font> shares of Common Stock and 2,776.5 shares of Series A Preferred Stock (convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,234,000</font> shares of Common Stock), along with a concurrent private placement of warrants to purchase Common Stock. The total net proceeds to the Company from this offering, after deducting the placement agent fees and offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.4</font> million. The warrants were initially exercisable on December 30, 2016, and expire on December 30, 2021. On February 21, 2017, the Company authorized the restart of sales under the At The Market Offering Agreement between the Company and H.C. Wainwright &amp; Co., LLC (the &#8220;ATM Agreement&#8221;) and subsequently sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 642,150</font> shares of Common Stock during the first quarter of 2017. No shares of Common Stock were sold pursuant to the ATM Agreement during the second or third quarters of 2017. The total net proceeds to the Company from this offering, after deducting the placement agent fees and offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million. On June 14, 2017, the Company completed a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,336,667</font> shares of Common Stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,995</font> shares of Series B Preferred Stock (convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,330,000</font> shares of Common Stock), along with warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,666,667</font> shares of Common Stock. The total net proceeds to the Company from the offering, after deducting the placement agent fees and offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.8</font> million. The warrants became exercisable upon issuance, and expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 14, 2022</font>. <i>See</i> Note 5, &#8220;Capital Stock&#8221;.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Effective July 31, 2015, the Company&#8217;s Common Stock began trading on The Nasdaq Capital Market under the symbol &#8220;EYEG&#8221;.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying Condensed Consolidated Financial Statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2017, EyeGate had Cash and Cash Equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,244,570</font>, and an Accumulated Deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,985,623</font>. EyeGate has incurred losses and negative cash flows since inception, and future losses are anticipated. The Company anticipates having sufficient cash to fund planned operations for approximately eight months, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although the Company successfully completed its IPO, a follow-on offering, a registered direct offering, a public offering, and sales under the ATM Agreement, additional capital may not be available on terms favorable to EyeGate, if at all. On May 6, 2016, the SEC declared effective EyeGate&#8217;s registration statement on Form S-3, registering a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000,000</font> of its securities for sale to the public from time to time in what is known as a &#8220;shelf offering&#8221;. The Company does not know if any future offerings pursuant to its shelf registration statement will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company&#8217;s recurring losses from operations have caused management to determine there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1 eyeg Proceeds From Upfront Payment
ProceedsFromUpfrontPayment
4000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for its clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2 eyeg Issuance Of Common Stockdescription
IssuanceOfCommonStockdescription
the Company is restricted from issuing any shares pursuant to the ATM Agreement for a period of twenty-four months following the closing date of the offering. However, this restriction is suspended for any sale of shares of Common Stock under the ATM Agreement that is above $3.00 per share.
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
188692 USD
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
153065 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
700833 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
390469 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.71 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
eyeg Write Off Of Stockholders Notes Receivable
WriteOffOfStockholdersNotesReceivable
-91054 USD
eyeg Write Off Of Stockholders Notes Receivable
WriteOffOfStockholdersNotesReceivable
0 USD
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
0 USD
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
11000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
31576 USD
eyeg Stockholder Debt Receivable Waiver
StockholderDebtReceivableWaiver
58824 USD

Files In Submission

Name View Source Status
0001144204-17-058607-index-headers.html Edgar Link pending
0001144204-17-058607-index.html Edgar Link pending
0001144204-17-058607.txt Edgar Link pending
0001144204-17-058607-xbrl.zip Edgar Link pending
eyeg-20170930.xml Edgar Link completed
eyeg-20170930.xsd Edgar Link pending
eyeg-20170930_cal.xml Edgar Link unprocessable
eyeg-20170930_def.xml Edgar Link unprocessable
eyeg-20170930_lab.xml Edgar Link unprocessable
eyeg-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv478795_10q.htm Edgar Link pending
tv478795_ex31-1.htm Edgar Link pending
tv478795_ex31-2.htm Edgar Link pending
tv478795_ex32-1.htm Edgar Link pending
tv478795_ex32-2.htm Edgar Link pending